Is CASBF or NOBL a better dividend investment in 2026?

CASBF currently yields 51.81% with a 5% 5-year dividend growth rate. NOBL yields 2.17% with 5% growth. The better choice depends on your goal: CASBF offers higher current income.

What is the dividend yield difference between CASBF and NOBL?

CASBF has a forward dividend yield of 51.81% ($2.00/share annually). NOBL yields 2.17% ($2.27/share annually). The yield gap is 49.64 percentage points.

Home › Compare › CASBF vs NOBL

CASBF vs NOBL: Dividend Comparison 2026

CASBF yields 51.81% · NOBL yields 2.17%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CASBF wins by $7.1K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CASBF

● Live price

51.81%

Share price

$3.86

Annual div

$2.00

5Y div CAGR

-50%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.0K

Annual income

$7.71

Full CASBF calculator →

NOBL

● Live price

2.17%

Share price

$104.67

Annual div

$2.27

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$22.9K

Annual income

$249.78

Full NOBL calculator →

Portfolio growth — CASBF vs NOBL

📍 CASBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CASBF	NOBL
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CASBF + NOBL cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CASBF pays

NOBL pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CASBF

Annual income on $10K today (after 15% tax)

$4,404.15/yr

After 10yr DRIP, annual income (after tax)

$6.55/yr

NOBL

Annual income on $10K today (after 15% tax)

$184.52/yr

After 10yr DRIP, annual income (after tax)

$212.31/yr

At 15% tax rate, NOBL beats the other by $205.76/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CASBF + NOBL for your $10,000?

CASBF: 50%NOBL: 50%

100% NOBL50/50100% CASBF

Portfolio after 10yr

$26.4K

Annual income

$128.74/yr

Blended yield

0.49%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CASBF buys

NOBL buys

No recent congressional trades found for CASBF or NOBL in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCASBFNOBL

Forward yield	51.81% ✓	2.17%
Annual dividend / share	$2.00	$2.27 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	-50%	0% ✓
Portfolio after 10y	$30.0K ✓	$22.9K
Annual income after 10y	$7.71	$249.78 ✓
Total dividends collected	$6.0K ✓	$2.3K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: CASBF vs NOBL ($10,000, DRIP)

Year	CASBF Portfolio	CASBF Income/yr	NOBL Portfolio	NOBL Income/yr	Gap
1← crossover	$13,291	$2,590.67	$10,917	$217.08	+$2.4K → CASBF
2	$15,830	$1,608.96	$11,903	$221.48	+$3.9K → CASBF
3	$17,834	$895.50	$12,962	$225.68	+$4.9K → CASBF
4	$19,553	$471.42	$14,099	$229.68	+$5.5K → CASBF
5	$21,164	$241.53	$15,319	$233.49	+$5.8K → CASBF
6	$22,767	$122.16	$16,628	$237.10	+$6.1K → CASBF
7	$24,422	$61.41	$18,033	$240.53	+$6.4K → CASBF
8	$26,163	$30.78	$19,539	$243.78	+$6.6K → CASBF
9	$28,010	$15.41	$21,154	$246.86	+$6.9K → CASBF
10	$29,978	$7.71	$22,884	$249.78	+$7.1K → CASBF

CASBF vs NOBL: Complete Analysis 2026

CASBF — Stock

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Full CASBF Calculator →

NOBL — ETF

The fund will invest at least 80% of its total assets in component securities of the index. The index contains a minimum of 40 stocks, which are equally weighted, and no single sector is allowed to comprise more than 30% of the index weight. It seeks to remain fully invested at all times in securities and/or financial instruments that, in combination, provide exposure to the returns of the index without regard to market conditions, trends or direction.

Full NOBL Calculator →

📬

Get this CASBF vs NOBL comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CASBF vs SCHD CASBF vs JEPI CASBF vs O CASBF vs KO CASBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.